AstraZeneca Clinical Study Information Center [clinicaltrials_resource:10543ee2afbb5dda4b9fa1c83633e27e]
clinicaltrials:NCT00579150Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes [clinicaltrials:NCT00658021]clinicaltrials:NCT00983619clinicaltrials:NCT01144338clinicaltrials:NCT01226316clinicaltrials:NCT01248949A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) [clinicaltrials:NCT01453205]A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0639 in Advanced Solid Tumors [clinicaltrials:NCT01577745]clinicaltrials:NCT01597388A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Brilinta [clinicaltrials:NCT01611272]clinicaltrials:NCT01625286A Phase 1/2 Study to Evaluate MEDI4736 [clinicaltrials:NCT01693562]clinicaltrials:NCT01750281clinicaltrials:NCT01808092clinicaltrials:NCT01809210clinicaltrials:NCT01829711clinicaltrials:NCT01884285Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment [clinicaltrials:NCT01894243]Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer [clinicaltrials:NCT01924533]clinicaltrials:NCT01933932A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours [clinicaltrials:NCT01938612]Prevention of Cardiovascular Events by Antiplatelet Agents After Acute Coronary Syndrome [clinicaltrials:NCT01952392]clinicaltrials:NCT01972217clinicaltrials:NCT01997450clinicaltrials:NCT02000622clinicaltrials:NCT02000947A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies [clinicaltrials:NCT02013804]clinicaltrials:NCT02022748Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone [clinicaltrials:NCT02027961]clinicaltrials:NCT02032823SAD/MAD Study to Assess Safety, Tolerability, PK & PD of MEDI1814 in Subjects With Mild-Moderate Alzheimer's Disease [clinicaltrials:NCT02036645]clinicaltrials:NCT02054130Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS Therapy [clinicaltrials:NCT02075255]clinicaltrials:NCT02087423clinicaltrials:NCT02088112A 12-Week Study in Asthmatic Children Ages 6 to <12 Years, Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared With Budesonide pMDI 80 μg [clinicaltrials:NCT02091986]Phase I Pharmacokinetics and Safety Study of Naloxegol in Paediatric OIC Patients [clinicaltrials:NCT02099591]clinicaltrials:NCT02104817Phase 1 Study to Evaluate MEDI4736 [clinicaltrials:NCT02117219]A Phase 1, Open-label Study to Evaluate the Safety and Tolerability of MEDI0680 (AMP-514) in Combination With MEDI4736 in Subjects With Advanced Malignancies [clinicaltrials:NCT02118337]
overall contact [clinicaltrials_vocabulary:overall-contact]
AstraZeneca Clinical Study Information Center [clinicaltrials_resource:10543ee2afbb5dda4b9fa1c83633e27e]
Bio2RDF identifier
10543ee2afbb5dda4b9fa1c83633e27e
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:10543ee2afbb5dda4b9fa1c83633e27e
affiliation [clinicaltrials_vocabulary:affiliation]
email [clinicaltrials_vocabulary:email]
information.center@astrazeneca.com
last name [clinicaltrials_vocabulary:last-name]
Alexander Bedenkov
Alexander Bedenkov, MCMD
Alexander Bedenkov, Medical Director
Andrew Tutt, Doctor of Medicine
Anitra Fielding
Anne-Laure Fedou
Annelize Koch, Dr
Annelize Koch, Dr.
Anthony Jarkowski III
AstraZeneca Clinical Study Information Center
phone [clinicaltrials_vocabulary:phone]
1-877-240-9479
phone ext [clinicaltrials_vocabulary:phone-ext]
role [clinicaltrials_vocabulary:role]
Principal Investigator
Study Chair
Study Director
identifier
clinicaltrials_resource:10543ee2afbb5dda4b9fa1c83633e27e
title
AstraZeneca Clinical Study Information Center
@en
Boyd Mudenda, MD
@en
Dominic Lai, MD
@en
Joe Parker, MD
@en
Nardev Khurmi, MD
@en
Paul Newell, MBBS, MRCP
@en
Serban Ghiorghiu, MSD
@en
Trishna Goswami, M.D.
@en
Vikki Brown, MD
@en
Yung-Jue Bang, MD
@en
type
label
AstraZeneca Clinical Study Inf ...... 43ee2afbb5dda4b9fa1c83633e27e]
@en
Boyd Mudenda, MD [clinicaltrials_resource:10543ee2afbb5dda4b9fa1c83633e27e]
@en
Dominic Lai, MD [clinicaltrials_resource:10543ee2afbb5dda4b9fa1c83633e27e]
@en
Joe Parker, MD [clinicaltrials_resource:10543ee2afbb5dda4b9fa1c83633e27e]
@en
Nardev Khurmi, MD [clinicaltrials_resource:10543ee2afbb5dda4b9fa1c83633e27e]
@en
Paul Newell, MBBS, MRCP [clinicaltrials_resource:10543ee2afbb5dda4b9fa1c83633e27e]
@en
Serban Ghiorghiu, MSD [clinicaltrials_resource:10543ee2afbb5dda4b9fa1c83633e27e]
@en
Trishna Goswami, M.D. [clinicaltrials_resource:10543ee2afbb5dda4b9fa1c83633e27e]
@en
Vikki Brown, MD [clinicaltrials_resource:10543ee2afbb5dda4b9fa1c83633e27e]
@en
Yung-Jue Bang, MD [clinicaltrials_resource:10543ee2afbb5dda4b9fa1c83633e27e]
@en